Uses of Ticoplan for Injection 200 mg: - Severe bacterial infections Gram-positive infection, CAPD-associated peritonitis Hypersensitivity.

Glycopeptide

Teicoplanin is a glycopeptide antibiotic that has shown in vitro bactericidal activity against both anaerobic and aerobic gram-positive organisms. Teicoplanin inhibits the growth of susceptible organisms by interfering with cell-wall biosynthesis at a site different from that affected by beta-lactams. It is active against staphylococci (including those resistant to methicillin and other beta-lactam antibiotics), streptococci, enterococci, Listeria monocytogenes, micrococci, group JK corynebacteria and gram-positive anaerobes including Clostridium difficile and peptococci.

How to use Teicoplanin: Your doctor or nurse will give you this medicine. Kindly do not self administer. Adult Dose: Parenteral Severe Gram-positive infections Adult: Initially, 6 mg/kg on first day, followed by 3 mg/kg/day. Severe infection: 6 mg/kg every 12 hr for the 1st 3 doses followed by 6 mg/kg/day. Doses may be given via IM inj, IV bolus or IV infusion over 30 minutes. Intravenous Prophylaxis of Gram-positive infection in high-risk patients undergoing surgery Adult: 400 mg as single dose at induction of anesth. Continuous ambulatory peritoneal dialysis (CAPD)-associated peritonitis Adult: If the patient is febrile, an initial loading dose of 400 mg may be given. Teicoplanin is added to the dialysis solution at a concentration of 20 mg/litre; dose is added into each bag of solution in the first wk, followed by alternate bags in the second wk and then in the overnight dwell bag in the third wk. Child Dose: Parenteral Severe Gram-positive infections Child: Loading dose: 10 mg/kg every 12 hr for 3 doses followed by 6-10 mg/kg/day depending on severity of the infection. Neonates: Loading dose: 16 mg/kg on the 1st day, followed by maintenance doses of 8 mg/kg/day by IV infusion. Renal Dose: Parenteral Renal impairment: Usual dose to be given for first 3 days, thereafter adjust dose according to CrCl. CrCl (ml/min) Dosage Recommendation 40-60 1/2 initial dose given daily or initial dose every 2 days. <40 1/3 initial dose given daily or initial dose every 3 days. Intravenous Renal impairment: Dose adjustment may be required.

Other nephrotoxic and/or neurotoxic drugs.

Hypersensitivity.

Common - Injection site reactions (pain, swelling, redness) - Fever - Itching - Skin rash Fever, chills, allergic reactions, GI disturbances, headache, dizziness, "red-man" syndrome, disturbances in liver enzymes, renal impairment, ototoxicity, blood dyscrasias. Pain, erythema, thrombophloebitis, abscess at site of admin. Potentially Fatal: Stevens-Johnson syndrome, toxic epidermal necrolysis.

There are no adequate and well-controlled studies in pregnant women about administration of Teicoplanin; this drug should be used during pregnancy only if clearly needed. Information about the excretion of Teicoplanin in milk is not known.

Precaution: Preexisting renal insufficiency, hypersensitivity to vancomycin. Perform periodic haematological studies, renal, LFT. Pregnancy, lactation.

Store at a temperature not exceeding 30°C in a dry place. Protect from light. The reconstituted solution should be used immediately, or stored under refrigeration (2 to 8° C) for 24 hours maximum.

Glycopeptide

Glycopeptide antibiotic with spectrum of activity is similar to vancomycin but teicoplanin may be more active in vitro against enterococci and some anaerobic organisms but some coagulase-negative Staphylococci are less sensitive to teicoplanin than to vancomycin.

Pregnancy Category B3. Teicoplanin should not be used during confirmed or presumed pregnancy or during lactation unless the potential benefits outweigh possible risks.